Summary & Overview
HCPCS Q4249: Amniply Topical Biologic, Per Square Centimeter
HCPCS Level II code Q4249 denotes Amniply, a topical biologic product billed per square centimeter as an add-on to a primary procedure. Nationally, this code matters because it captures the use of a specific topical adjunct that can affect procedural supply costs and clinical documentation for wound or tissue surface management during surgery. Accurate use of Q4249 ensures that the additional material applied topically is recorded and billed separately from the main procedure.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national perspective on clinical context for topical biologic adjuncts, billing characterization for add-on HCPCS items, and typical site-of-service implications. The publication summarizes benchmarks where available, notes common modifier usage patterns (input provided), and outlines documentation and coding considerations tied to use as an add-on product.
This overview is intended for health plans, hospital billing teams, and clinicians involved in perioperative supply documentation. It provides concise guidance on the code's purpose, the types of encounters where it is used, and the payer landscape relevant to reimbursement and claims processing. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code Q4249 describes Amniply, for topical use only, per square centimeter (add-on, list separately in addition to primary procedure). This code represents a topical biologic product intended for application to tissue surfaces as an adjunct to a primary procedure. The service type is topical biologic therapy applied during a surgical or procedural encounter, and the typical site of service is the operating room or procedure suite where the primary procedure is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing partial-thickness wound or a superficial surgical wound requiring advanced topical biologic therapy to promote epithelialization. The patient presents to an outpatient wound care clinic or ambulatory surgical center after conservative measures (dressings, debridement, antibiotic therapy if indicated) have not produced satisfactory healing. The clinician assesses the wound size and determines that a topical amniotic-derived product (Amniply) applied directly to the wound bed will be used as an adjunct to standard wound care.
The clinical workflow includes a pre-procedure evaluation (wound history, vascular and glycemic optimization, medication review), wound bed preparation with sharp or enzymatic debridement as indicated, hemostasis, measurement of wound surface area in square centimeters (product billed per cm2), sterile application of the amniotic topical per manufacturer instructions, and placement of an appropriate secondary dressing. The patient receives wound care education and a plan for follow-up visits for reassessment and repeat applications if clinically indicated. Typical sites of service are outpatient wound care clinics, physician offices, and ambulatory procedure centers where topical biologic dressings are applied in a non-implantable, non-injectable manner.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default - No modifier | Use when no special billing modifier applies. |